17 results
8-K
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
ITEM 8.01 OTHER
8-K
RVNC
Revance Therapeutics Inc
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely
8-K
EX-99.1
RVNC
Revance Therapeutics Inc
27 Nov 20
Other Events
1:50pm
are subject to qualifications and exceptions contained herein relating to materiality or Material Adverse Effect, are true and correct at the time of delivery … A) to the extent such representations and warranties are subject to qualifications and exceptions contained herein
relating to materiality or Material Adverse
S-4/A
1pqrp6nz
23 Jun 20
Registration of securities issued in business combination transactions (amended)
6:09am
S-4
b8c5z437vd6hckp
9 Jun 20
Registration of securities issued in business combination transactions
9:48pm
424B3
maqk0kaqo3 dqo
24 Jun 20
Prospectus supplement
5:18pm
S-1
EX-10.12
wrbvwpn45fckh
31 Dec 13
IPO registration
12:00am
DRS
EX-10.12
vvftlgpwnga
19 Apr 13
Draft registration statement
12:00am
- Prev
- 1
- Next